- STAT+: Pharma tries to tamp down broad China restrictionsAI-focused VC firm raises $800M, Merck's new cholesterol pill, and more biotech news from The ReadoutSTAT · 6d ago↗ source
- Mentari adds $200M to migraine mission; Royalty's latest ATTR-CM dealAnother $200M for Mentari: Migraine drug developer Mentari Therapeutics has lined up a second private placement as it works to close its reverse merger with InMed Pharmaceuticals. The Paragon Thera…Endpoints · 6d ago↗ source
- Repligen strikes $1.5B BioLife buyout to bag cell therapy product pharmas rely onTop-selling cell therapies from BMS, J&J and Gilead depend on a BioLife product, positioning Repligen to use the takeover to increase its exposure to the modality.BioSpace · 6d ago